BridgeBio Pharma Inc
BBIO: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$63.17 | Sflf | — |
Early-Stage Biotech BridgeBio's Acoramidis Drives Valuation for Long-Term Investors
Business Strategy and Outlook
BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.